Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abbott

- PMLiVE

Pfizer acquires option to license potential Parkinson’s treatment

Medgenesis cuts exclusive deal for its GDNF treatment

- PMLiVE

Pharma takes the ALS Ice Bucket Challenge

GSK, Evotec and Biogen Idec participate in the social media sensation

- PMLiVE

Mylan buys Abbott’s non-US generics in $5.3bn deal

Lower tax rate drives bid to create new firm based in Netherlands

- PMLiVE

Abbott offers up to $495m for Russia’s Veropharm

Acquisition will add to its generics portfolio

- PMLiVE

Abbott strikes $3.3bn Latin America generics deal

Boosts portfolio in region with acquisition of CFR Pharmaceuticals

- PMLiVE

Lundbeck agrees $658m deal to buy Chelsea Therapeutics

Acquisition boosts Danish firm's neurology profile and presence in US

- PMLiVE

AbbVie sales jump on strong Humira gains

Extra indications help boost performance of treatment for autoimmune disorders

- PMLiVE

Abbott and GSK announce job cuts in Ireland

Nearly 300 positions to go in Cork and Tipperary

- PMLiVE

AbbVie expects Humira to drive growth in inaugural guidance

First statement since split from Abbott

- PMLiVE

Matt Regan named AbbVie’s general manager in UK

Was formerly general manager of Abbott in Norway

- PMLiVE

Abbott completes split as AbbVie debuts on NYSE

New company will focus on research-based pharmaceuticals

- PMLiVE

AstraZeneca’s fostamatinib fails to match Humira in RA

Inferiority to Abbott’s drug dents commercial prospects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links